N06.4 Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis

✓ Billable ICD-10-CM 2026
Open N06.4 in Web App →

The ICD-10-CM code for Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis is N06.4 (FY2026). It is a billable, claim-ready diagnosis code.

Classification

Section
N00-N08: Glomerular diseases (N00-N08)
Category N06
16 codes (14 billable)
FY2026 Status
Stable since FY2024

Also Known As

ICD-10-CM Alphabetic Index entries that lead to N06.4:

  • Proteinuria › isolated › with glomerular lesion › diffuse › endocapillary proliferative glomerulonephritis

U.S. Hospital Utilization

N06.4 appeared in too few sampled U.S. inpatient stays in 2022 to report a national estimate (AHRQ suppresses counts of 10 or fewer) — a rare inpatient diagnosis.

Source: National Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality, 2016–2023. National survey-weighted estimates.

Official Coding Guidelines

CKD staging and code assignment (N18.-)

The ICD-10-CM classifies CKD based on severity. The severity of CKD is designated by stages 1-5. Stage 2, code N18.2, equates to mild CKD; stage 3, codes N18.30-N18.32, equate to moderate CKD; and stage 4, code N18.4, equates to severe CKD. Code N18.6, End stage renal disease (ESRD), is assigned when the provider has documented end- stage renal disease (ESRD).

— ICD-10-CM Official Guidelines for Coding and Reporting, FY2026, Section I.C.14.a.1
CKD stage plus ESRD: assign N18.6 only

If both a stage of CKD and ESRD are documented, assign code N18.6 only.

— ICD-10-CM Official Guidelines for Coding and Reporting, FY2026, Section I.C.14.a.1

Source: CMS — ICD-10-CM Official Guidelines for Coding and Reporting, FY2026

References

Related Codes

Search all 70,000+ ICD-10-CM codes →
Reviewed by Prajwal Shrestha, CPC, CRC
Certified Professional Coder (CPC) and Certified Risk Adjustment Coder (CRC) · AAPC Member ID 01997614 · About · Editorial policy · Content last reviewed: 2025-10-01

Get HCC Mappings, Clinical Summaries, and More

Access premium features including HCC risk adjustment, FDA drug indications, AI coding assistant, and comprehensive clinical context.

Start Free Trial